Multiple Myeloma Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

Multiple Myeloma Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, about 100+ key pharma and biotech companies are working on 130+ pipeline drugs in the Multiple Myeloma therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Multiple Myeloma Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Multiple Myeloma Market. 

The Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Multiple Myeloma Pipeline Analysis

Multiple Myeloma Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Multiple Myeloma and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Multiple Myeloma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage products (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Multiple myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Intravenous

  • Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

  • Small molecule

  • Cell Therapy

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy


Learn How the Ongoing Clinical & Commercial Activities will Affect the Multiple Myeloma Therapeutic Segment @

Multiple Myeloma Therapeutics Landscape

There are approx. 100+ key companies developing therapies for Multiple myeloma. Currently, Janssen Pharmaceuticals is leading the therapeutics market with its Multiple myeloma drug candidates in the most advanced stage of clinical development.

The Leading Players in the Multiple Myeloma Therapeutics Market Include:

Abbvie (Pharmacyclics), Arcellx, Arch Oncology, Ascentage Pharma, AstraZeneca, Biokine Therapeutics, BioLineRx, Bristol-Myers Squibb/Celgene, CARsgen, Cartesian Therapeutics, Celgene, Cellectar Biosciences, Chipscreen Biosciences, Cytovia Therapeutics, ExCellThera, GlaxoSmithKline, Glenmark (Ichnos Sciences SA), Gracell Biotechnology, Incyte Corporation, iTeos Therapeutics, Janssen Biotech, Juno Therapeutics, Karyopharm Therapeutics, Merck Sharp & Dohme Corp., Molecular Partners AG, MorphoSys, MorphoSys AG/I-Mab Biopharma, Nanjing IASO Biotherapeutics, Nerviano Medical Sciences, Novartis, Oncoceutics, Oncopeptides AB, Pfizer (Array Biopharma), Poseida Therapeutics, Precision BioSciences, RAPA Therapeutics, Regeneron Pharmaceuticals, Sana Biotechnology, Sanofi, Secura Bio, Sorrento Therapeutics, SpringWorks Therapeutics, Takeda Pharmaceutical (Millennium Pharmaceuticals), TeneoBio, and others.

Multiple Myeloma Emerging and Marketed Drugs Covered in the Report Include:

  • Elranatamab: Pfizer

  • Felzartamab: Janssen Pharmaceutical

  • Venclexta/Venclyxto: Venetoclax 

  • TNB-383B/ABBV 383: Abbvie 

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Latest Key Update in the Multiple Myeloma Therapeutics Market

On April 11, 2023, Oncolyze, which already holds an Orphan Drug Designation for its lead drug candidate OM-301 in treating acute myeloid leukemia (AML), announced that the FDA has just granted OM-301 its second Orphan Drug Designation for multiple myeloma.

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Multiple Myeloma Current Treatment Patterns

4. Multiple Myeloma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Multiple Myeloma Late Stage Products (Phase-III)

7. Multiple Myeloma Mid-Stage Products (Phase-II)

8. Multiple Myeloma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Multiple Myeloma Discontinued Products

13. Multiple Myeloma Product Profiles

14. Key Companies in the Multiple Myeloma Market

15. Key Products in the Multiple Myeloma Therapeutics Segment

16. Dormant and Discontinued Products

17. Multiple Myeloma Unmet Needs

18. Multiple Myeloma Future Perspectives

19. Multiple Myeloma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Take control of your pharmaceutical portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Services 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States